drugset
Drugs / 21-valent pneumococcal conjugate vaccine
last change Jan 2026 re-read 3 minutes ago

21-valent pneumococcal conjugate vaccine

Vaccine

Investigated by
Merck Sharp & Dohme LLC · VA Sierra Nevada Health Care System

Trials 1

today NCT06271681 · Ph 4
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT06271681 Jan 2026 → Jan 2027 expected immunodeficiency disease VA Sierra Nevada Health Care System Not yet recruiting No outcome recorded

Press releases naming this drug 6 releases

DateIssuerRelease
2024-04-29 Merck Sharp & Dohme LLC Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults merck.com ↗
2024-03-19 Merck Sharp & Dohme LLC Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults merck.com ↗
2023-12-19 Merck Sharp & Dohme LLC FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults merck.com ↗
2023-11-28 Merck Sharp & Dohme LLC Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older merck.com ↗
2023-07-27 Merck Sharp & Dohme LLC Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials merck.com ↗
2022-04-14 Merck Sharp & Dohme LLC Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults merck.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 21-valent pneumococcal conjugate vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT06271681 ↗
Modality Vaccine “21-valent pneumococcal conjugate vaccine” NCT06271681 ↗